These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8917631

  • 21. The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
    Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, Colombo MP, Parmiani G.
    Int J Cancer; 1991 Mar 12; 47(5):746-54. PubMed ID: 1706327
    [Abstract] [Full Text] [Related]

  • 22. The significance of heregulin in breast cancer tumor progression and drug resistance.
    Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C.
    Breast Cancer Res Treat; 1996 Mar 12; 38(1):57-66. PubMed ID: 8825123
    [Abstract] [Full Text] [Related]

  • 23. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M, Spatafora M, Melodia A, Pace E, Gjomarkaj M, Merendino AM, Bonsignore G.
    Eur Respir J; 1996 Sep 12; 9(9):1831-8. PubMed ID: 8880099
    [Abstract] [Full Text] [Related]

  • 24. Lymphokine-activated killer (LAK)-mediated lysis of sequentially isolated ovarian cancer cell lines.
    Yashar CM, Taylor DD, Gibb RK, Gerçel-Taylor C.
    Am J Reprod Immunol; 1997 Dec 12; 38(6):431-7. PubMed ID: 9412727
    [Abstract] [Full Text] [Related]

  • 25. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
    Galandrini R, Albi N, Zarcone D, Grossi CE, Velardi A.
    Eur J Immunol; 1992 Aug 12; 22(8):2047-53. PubMed ID: 1379184
    [Abstract] [Full Text] [Related]

  • 26. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
    Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K.
    Oncogene; 1996 Jun 20; 12(12):2535-47. PubMed ID: 8700512
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E, Thomas X, Campos L, Fiere D, Doré JF.
    Leuk Res; 1992 Jun 20; 16(6-7):673-80. PubMed ID: 1378919
    [Abstract] [Full Text] [Related]

  • 30. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
    Ram TG, Kokeny KE, Dilts CA, Ethier SP.
    J Cell Physiol; 1995 Jun 20; 163(3):589-96. PubMed ID: 7775601
    [Abstract] [Full Text] [Related]

  • 31. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
    Mincione G, Piccirelli A, Lazzereschi D, Salomon DS, Colletta G.
    J Cell Physiol; 1998 Aug 20; 176(2):383-91. PubMed ID: 9648926
    [Abstract] [Full Text] [Related]

  • 32. The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid.
    Alexander CL, Edward M, MacKie RM.
    Br J Cancer; 1999 Jul 20; 80(10):1494-500. PubMed ID: 10408388
    [Abstract] [Full Text] [Related]

  • 33. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants.
    Gross N, Favre S, Beck D, Meyer M.
    Int J Cancer; 1992 Aug 19; 52(1):85-91. PubMed ID: 1354203
    [Abstract] [Full Text] [Related]

  • 34. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A, Yagita H, Matsuda H, Okumura K, Niitani H.
    Cancer Res; 1992 Sep 15; 52(18):4890-4. PubMed ID: 1381273
    [Abstract] [Full Text] [Related]

  • 35. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T.
    Anticancer Res; 2005 Sep 15; 25(2A):827-32. PubMed ID: 15868915
    [Abstract] [Full Text] [Related]

  • 36. [LAK sensitivity of human pancreas carcinoma cell lines].
    Sugiura H.
    Hokkaido Igaku Zasshi; 1993 Nov 15; 68(6):921-34. PubMed ID: 7906667
    [Abstract] [Full Text] [Related]

  • 37. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 38. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells.
    Fujiwara T, Loudon WG, Grimm EA.
    Lymphokine Cytokine Res; 1993 Feb 27; 12(1):45-8. PubMed ID: 8096153
    [Abstract] [Full Text] [Related]

  • 39. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
    Gwin JL, Gercel-Taylor C, Taylor DD, Eisenberg B.
    J Surg Res; 1996 Jan 27; 60(1):129-36. PubMed ID: 8592403
    [Abstract] [Full Text] [Related]

  • 40. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3.
    Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, Benz CC, Lupu R.
    Int J Oncol; 1999 Nov 27; 15(5):883-92. PubMed ID: 10536169
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.